within Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AK07_FormoterolAndBudesonide;

model FormoterolAndBudesonide
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 2.777777777777778e-05,
    adminDuration = 600,
    adminMass = 12 / 1000000,
    adminCount = 1,
    Vd = 0.2,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.16,
    k12 = 1.9444444444444445e-05,
    k21 = 1.9444444444444445e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>FormoterolAndBudesonide</td></tr><tr><td>ATC code:</td><td>R03AK07</td></tr><td>route:</td><td>inhalation</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>12</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>200</td><td>L</td></tr>
    <tr><td>clearance:</td><td>100</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Formoterol and budesonide is a fixed-dose combination inhaler containing formoterol, a long-acting beta2-adrenoceptor agonist, and budesonide, an inhaled corticosteroid. This combination is widely used for the regular treatment and prevention of asthma and chronic obstructive pulmonary disease (COPD). It is approved and commonly prescribed worldwide.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after inhaled administration of formoterol/budesonide combination.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R03AK07 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end FormoterolAndBudesonide;
